# Ceftriaxone ```text DRUG INFORMATION ADULT - ( 2.1 ) Recommended Dosing Schedule for Ceftriaxone for Injection and Dextrose Injection Site and Type of Infection Dose Frequency Total Daily Dose Usual Adult Dose 1 g to 2 g once a day or in equally divided doses every 12 hours should not exceed 4 g Patients with hepatic impairment and significant renal impairment should not receive more than 2 grams per day of ceftriaxone. Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'dosage and administration', retrieved 2026-08-29 - Table 1: Recommended Dosing Schedule for Ceftriaxone for Injection and Dextrose Injection Site and Type of Infection Dose Frequency Total Daily Dose Usual Adult Dose 1 g to 2 g once a day or in equally divided doses every 12 hours should not exceed 4 g Patients with hepatic impairment and significant renal impairment should not receive more than 2 grams per day of ceftriaxone. Source: This line points to a numbered table that this card does not show - read that table in the label before you dose. US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'dosage and administration', retrieved 2026-08-29 CHILD - Ceftriaxone for Injection and Dextrose Injection in the DUPLEX® Container is designed to deliver a 1 g or 2 g dose of ceftriaxone. To prevent unintentional overdose, this product should not be used in pediatric patients who require less than the full 1 g or 2 g adult dose of ceftriaxone. Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'pediatric use', retrieved 2026-08-29 - To prevent unintentional overdose, this product should not be used in pediatric patients who require less than the full 1 g or 2 g adult dose of ceftriaxone. Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'pediatric use', retrieved 2026-08-29 RENAL IMPAIRMENT - ( 2.1 ) Recommended Dosing Schedule for Ceftriaxone for Injection and Dextrose Injection Site and Type of Infection Dose Frequency Total Daily Dose Usual Adult Dose 1 g to 2 g once a day or in equally divided doses every 12 hours should not exceed 4 g Patients with hepatic impairment and significant renal impairment should not receive more than 2 grams per day of ceftriaxone. Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'dosage and administration', retrieved 2026-08-29 - Table 1: Recommended Dosing Schedule for Ceftriaxone for Injection and Dextrose Injection Site and Type of Infection Dose Frequency Total Daily Dose Usual Adult Dose 1 g to 2 g once a day or in equally divided doses every 12 hours should not exceed 4 g Patients with hepatic impairment and significant renal impairment should not receive more than 2 grams per day of ceftriaxone. Source: This line points to a numbered table that this card does not show - read that table in the label before you dose. US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'dosage and administration', retrieved 2026-08-29 - Hepatic and renal impairment Patients with both hepatic and renal impairment should not receive more than 2 grams of ceftriaxone per day ( 5.8 ) Pediatric Patients Ceftriaxone for Injection and Dextrose Injection in the DUPLEX® Container is designed to deliver a 1 g or 2 g dose of ceftriaxone. Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'use in specific populations', retrieved 2026-08-29 HEPATIC IMPAIRMENT - ( 2.1 ) Recommended Dosing Schedule for Ceftriaxone for Injection and Dextrose Injection Site and Type of Infection Dose Frequency Total Daily Dose Usual Adult Dose 1 g to 2 g once a day or in equally divided doses every 12 hours should not exceed 4 g Patients with hepatic impairment and significant renal impairment should not receive more than 2 grams per day of ceftriaxone. Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'dosage and administration', retrieved 2026-08-29 - Table 1: Recommended Dosing Schedule for Ceftriaxone for Injection and Dextrose Injection Site and Type of Infection Dose Frequency Total Daily Dose Usual Adult Dose 1 g to 2 g once a day or in equally divided doses every 12 hours should not exceed 4 g Patients with hepatic impairment and significant renal impairment should not receive more than 2 grams per day of ceftriaxone. Source: This line points to a numbered table that this card does not show - read that table in the label before you dose. US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'dosage and administration', retrieved 2026-08-29 - The pharmacokinetics of ceftriaxone were only minimally altered in geriatric patients compared to healthy adult subjects and dosage adjustments are not necessary for geriatric patients with ceftriaxone dosages up to 2 grams per day, provided there is no severe renal and hepatic impairment. [see Clinical Pharmacology (12) ] Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'use in specific populations', retrieved 2026-08-29 PREGNANCY - Risk Summary Available data from published prospective cohort studies, case series, and case reports over several decades with cephalosporin use, including Ceftriaxone, in pregnant women have not established a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'pregnancy', retrieved 2026-08-29 - In animal reproduction studies, no adverse developmental effects were observed when ceftriaxone was administered to pregnant rats at doses up to approximately 2.8 times the clinical dose of 2 g/day (see Data) . Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'pregnancy', retrieved 2026-08-29 - The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'pregnancy', retrieved 2026-08-29 BREASTFEEDING - No adverse effects were noted on various reproductive parameters during gestation and lactation, including postnatal growth, functional behavior, and reproductive ability of the offspring. 8.2 Lactation Risk Summary Data from published literature report that ceftriaxone is present in human milk. Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'use in specific populations', retrieved 2026-08-29 - There are no data on the effects of Ceftriaxone on the breastfed child or on milk production. Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'use in specific populations', retrieved 2026-08-29 - The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for Ceftriaxone for Injection and Dextrose Injection and any potential adverse effects on the breastfed child from Ceftriaxone for Injection and Dextrose Injection or from the mother’s underlying condition. Source: US FDA label for ceftriaxone (CEFTRIAXONE AND DEXTROSE), section 'use in specific populations', retrieved 2026-08-29 ``` --- Dawaa Reference is a reference for prescribers, not a medical device, and does not replace clinical judgement. [Privacy policy](/privacy)